HC Wainwright Has Lowered Expectations for COMPASS Pathways (NASDAQ:CMPS) Stock Price

Key Points

• HC Wainwright has reduced the price target for COMPASS Pathways (NASDAQ:CMPS) from $45.00 to $40.00, while maintaining a "buy" rating on the stock.
• COMPASS Pathways reported a quarterly loss of ($0.38) earnings per share, slightly below analysts' estimates, with a current forecast of -2.33 EPS for the fiscal year.
• The stock is currently trading around $4.74 with a market capitalization of $443.86 million and significant recent institutional investment increases.

COMPASS Pathways (NASDAQ:CMPS - Free Report) had its price target decreased by HC Wainwright from $45.00 to $40.00 in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for COMPASS Pathways' Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.68) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.91) EPS, FY2027 earnings at ($0.96) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $1.00 EPS.

A number of other research firms have also recently weighed in on CMPS. Cantor Fitzgerald reiterated an "overweight" rating and set a $12.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, May 27th. Evercore ISI reissued an "in-line" rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $15.00 price target on shares of COMPASS Pathways in a research note on Friday, August 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.29.

COMPASS Pathways Price Performance

NASDAQ CMPS traded up $0.06 on Monday, reaching $4.37. The company had a trading volume of 347,528 shares, compared to its average volume of 1,816,530. The firm's 50 day moving average price is $4.01 and its 200 day moving average price is $3.83. COMPASS Pathways has a 12 month low of $2.25 and a 12 month high of $8.54. The stock has a market capitalization of $418.78 million, a PE ratio of -2.38 and a beta of 2.17. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, equities analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CMPS. Virtus ETF Advisers LLC boosted its stake in COMPASS Pathways by 21.4% in the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock worth $61,000 after purchasing an additional 2,840 shares in the last quarter. Flagship Harbor Advisors LLC increased its position in shares of COMPASS Pathways by 27.7% during the 1st quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after purchasing an additional 3,134 shares during the last quarter. Conservest Capital Advisors Inc. lifted its position in COMPASS Pathways by 32.5% in the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company's stock valued at $57,000 after buying an additional 5,000 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after acquiring an additional 5,003 shares during the period. Finally, Kennedy Capital Management LLC raised its position in COMPASS Pathways by 22.8% in the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock valued at $128,000 after purchasing an additional 6,297 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.